Syndesis Health
NEW YORK, NY / ACCESSWIRE / May 11, 2023 / Syndesis Health announced today that it has signed a research collaboration and information sharing agreement with Fundación Cardio Infantil Instituto de Cardiología (LaCardio), a leading cardiovascular hospital in Bogotá, Colombia.
LaCardio is joining the Syndesis Health Network alongside progressive healthcare institutions from South America, Asia, and Africa. Syndesis Health created its global network of healthcare partners to enable secure access to a multi-country, real-world data set. Syndesis Health's global research platform, Syntium, unifies de-identified clinical data from these healthcare partners in a secure, ethical, and compliant manner for the improvement of global health outcomes.
The partnership enables LaCardio to extend its commitment to improving patient outcomes by leveraging the Syndesis Health platform for access to data, analytics, and other technical resources. In addition, the partnership enables the hospital to engage in collaborative research opportunities with peer institutions around the world that are a part of the network.
Hans Godfrey, COO and head of Latin America data partnerships for Syndesis Health, commented: "We believe that the future of healthcare will be data-driven. With LaCardio as a partner in the Syndesis Health Network, we will together expand the potential for real-world data to enable research and treatments in the cardiovascular space."
Dr. Juan Gabriel Cendales, Executive Director of LaCardio, stated: "One of the strategic priorities of LaCardio as a university hospital and scientific research center is to continue advancing in scientific studies while contributing to the health of the people in Colombia and the region. Having valuable data, evaluating, and applying tools, such as AI, in healthcare allows us to anticipate the needs of the population, evaluate new alternatives and improve the experience of patients and collaborators. This alliance is part of the path in which we are working to be the hospital of the future."
About Syndesis Health
Syndesis Health accelerates research and innovation for healthcare and life sciences companies. The company was founded on the potential for real-world clinical data to advance medical research, improve patient health outcomes, and inform healthcare policy decisions. The Syndesis Health Network enables secure collaboration amongst member organizations and is powered by Syntium, the Syndesis data platform. Visit our website at https://syndesis.com to learn more.
About LaCardio
Fundación Cardioinfantil-LaCardio is a private, nonprofit institution with 50 years of experience. Founded in 1973 by brothers Reinaldo and Camilo Cabrera Polanía, it is one of the few Colombian institutions accredited by the Joint Commission International and has national accreditation granted by ICONTEC. Since 2015, LaCardio is recognized as a University Hospital by the Intersectoral Committee for Human Talent in Health, in compliance of the Ministries of Health and Education of Colombia. Its commitment to health transcends through its mission: to operate on low-income children with heart problems. The MERCO 2022 ranking positioned LaCardio as the best hospital in Colombia. In 2021, Americaeconomia ranked LaCardio 5th in Latin America, evaluating key processes and indicators, including patient safety & dignity, human capital, capacity, and knowledge management.
Contact Information
Leah Patterson
Chief Marketing Officer
leah.patterson@syndesis.com
+1.646.274.1420
Liliana Milena Toro Sánchez Sánchez
Marketing & Communications
lmtoro@lacardio.org
+3157288712
SOURCE: Syndesis Health
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/754175/Syndesis-Health-LaCardio-Sign-Research-Collaboration-Agreement
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
eComplete Partners with Sourceful to build AI-Native Creative Operations Across Portfolio18.11.2025 15:00:00 CET | Press release
MANCHESTER, UK / ACCESS Newswire / November 18, 2025 / eComplete, the private equity firm behind Current Body's £300 million London Stock Exchange listing, has announced a strategic partnership with Sourceful, the Manchester-based technology company whose Riverflow 1 model ranks as the world's leading AI image editing model. The partnership brings Sourceful's AI-native creative platform to eComplete's portfolio of direct-to-consumer brands, enabling them to generate brand-accurate, production-ready creative assets at scale across e-commerce, social, marketplace and retail. This makes eComplete the first major private equity investor to adopt AI-native creative infrastructure as a core operational advantage. Why this matters Every consumer brand today faces the same constraint: producing thousands of creative assets, product images, ads, videos, packaging, that feel authentically on-brand across every channel and market. This challenge has intensified dramatically over the past three ye
IXOPAY Appoints George Hansen as Chief Revenue Officer to Accelerate Global Growth in Tokenization, Orchestration, and Compliance18.11.2025 06:00:00 CET | Press release
Seasoned payments executive joins IXOPAY to lead global revenue strategy amid rapid growth and the rise of agentic commerce. LEHI, UTAH / ACCESS Newswire / November 18, 2025 / IXOPAY, a global leader in enterprise-grade payment orchestration, today announced the appointment of George Hansen as Chief Revenue Officer (CRO). A veteran of the payments and fintech industries, Hansen brings more than two decades of leadership experience driving growth, transformation, and customer-centric innovation at a global scale. In his new role, Hansen will drive IXOPAY's global revenue strategy, leading sales and partnerships and aligning with marketing and customer success to support enterprise merchants and partners worldwide. His appointment reinforces IXOPAY's commitment to giving merchants full control of their payment strategy through a vendor-neutral architecture designed for scale, flexibility, and intelligence. Hansen has held senior leadership positions at companies including American Expres
General Holdings Limited and NewOak Capital Form Strategic Joint Venture to Launch CMXG, an $800M Commodities Investment Platform18.11.2025 06:00:00 CET | Press release
DUBAI, AE / ACCESS Newswire / November 18, 2025 / General Holdings Limited (GH), a Dubai International Financial Centre-based multi-strategy private investment holding company, and NewOak Capital LLC, a New York collateralized private debt asset management and structured financing and capital markets firm, today announced the formation of Common Commodities CMXG (CMXG), a vertically integrated tech-enabled commodities investment platform designed to deliver risk-controlled, scalable institutional commodity-linked real yield and growth equity to qualified global investors. The partnership combines General Holdings' strategic capital and governance expertise with NewOak Capital's structured asset-based supply-chain financing capabilities and distribution platform. This sets the foundation for "a globally scalable, integrated and transparent institutional trade finance platform facilitating sustainable and inclusive cross-regional growth." Strategic Capital Deployment and Fund Launch CMXG
OBI-902 Has Been Granted by US FDA for Orphan Drug Designation for the Treatment of Cholangiocarcinoma17.11.2025 13:00:00 CET | Press release
OBI-902 is the first ADC utilizing OBI's proprietary GlycOBI® glycan-based ADC enabling technology for evaluation of safety and efficacy in patients with Cancer. TAIPEI, TW / ACCESS Newswire / November 17, 2025 / OBI Pharma, a clinical-stage oncology company (4174.TWO) received notification from the US FDA stating that the request for Orphan Drug Designation of OBI-902 TROP2 ADC for the treatment of Cholangiocarcinoma has been granted. OBI-902 is the first OBI-developed ADC that incorporates our proprietary site-specific glycan-conjugated ADC enabling technology. Cholangiocarcinoma is a rare and lethal malignancy with fewer than 50,000 patients in the United States and a 5-year survival rate ranging from 2% and 23% depending on disease stage, histological subtype, and localization 1 . At present, there are no FDA approved ADC therapies for cholangiocarcinoma. To encourage the industry to develop new treatment options for rare diseases, the US FDA grants Orphan Drug Designation to exper
Camino Completes C$5.6 Million Investment with Strategic Investors17.11.2025 12:00:00 CET | Press release
VANCOUVER, BC / ACCESS Newswire / November 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC:CAMZF) ("Camino" or the "Company") is pleased to announce the closing of its -brokered private placement (the "Financing") of common shares in the capital of the Company (the "Shares") previously announced in its news release dated November 12, 2025. Under the Financing, the Company issued an aggregate of 15,554,666 Shares at an issue price of $0.36 per Share, for aggregate gross proceeds of C$5,599,680. Participants in the Financing included two new key shareholders, Elemental Royalties (formerly EMX Royalty Corp.) and Continental General Insurance Company, as well as certain insiders of Camino. The gross proceeds of the Financing will be applied towards corporate working capital, legal expenses, engineering studies, project development, and general administrative expenses. The Shares issued pursuant to the Financing are subject to a statutory hold period expiring on March 15, 2026, in acc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom